Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Interest Expense : $-20.8 Mil (TTM As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Arrowhead Pharmaceuticals's interest expense for the three months ended in Dec. 2023 was $ -5.4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-20.8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Arrowhead Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $ -136.5 Mil. Arrowhead Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $ -5.4 Mil. Arrowhead Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Arrowhead Pharmaceuticals Interest Expense Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Interest Expense Chart

Arrowhead Pharmaceuticals Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Interest Expense

Get a 7-Day Free Trial

-18.33

Arrowhead Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-2.85	-5.06	-5.16	-5.26	-5.37

Arrowhead Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.8 Mil.

Arrowhead Pharmaceuticals (NAS:ARWR) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Arrowhead Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-5.4 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-136.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $115.2 Mil.

Arrowhead Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Arrowhead Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

HDP1:Germany

Address

177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105

Website

https://www.arrowheadpharma.com

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Executives

James C Hamilton	other: Senior Vice President	177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
Victoria Vakiener	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Mauro Ferrari	director	201 SOUTH LAKE AVENUE, PASADENA CA 91101
William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given	director	C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Tracie Oliver	officer: Chief Commercial Officer	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Patrick O'brien	officer: General Counsel	225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
Martin Javier San	officer: Chief Medical Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Kenneth Allen Myszkowski	officer: CFO	ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Christopher Richard Anzalone	director, officer: President and CEO	ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Backer Marianne De	director	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Michael S Perry	director	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
James Hassard	officer: Chief Commercial Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw	officer: Chief Scientific Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105